Oncology

Blood cells
#ASH 2025 #CAR-T #Events #Haematology #Oncology

ASH 2025: New clinical findings in haematology

The 67th American Society of Hematology (ASH) Annual Meeting and Exposition took place 6-9 December 2025, in Orlando, Florida. Diana Turner rounds up the latest clinical trial data shared at the meeting.  Early-stage trials KLN-1010 for multiple myeloma Kelonia Therapeutics announced the first results from the ongoing inMMyCAR study, a… Read More

#Exclusive Content

#Antibodies #Genmab #Mergers and acquisitions #Oncology

Genmab closes its $8 billion acquisition of Merus

Genmab has announced that the conditions to acquire all the issued and outstanding common shares of Merus for $97 per common share in cash have been satisfied.   The company says the transaction diversifies its revenue and will drive sustained growth into the next decade.  With the acquisition, Genmab adds petosemtamab… Read More

#Business & Investment #News

Acute lymphoblastic leukemia
#ASH 2025 #Clinical trial #Leukaemia #Oncology

Pirtobrutinib more effective than ibrutinib, study finds 

A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib).  The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More

#Cancer Research #News

Chronic myeloid leukaemia
#ASH 2025 #Leukaemia #Oncology

Drug shows ‘unprecedented’ response in chronic myeloid leukaemia 

Oncology company Terns Pharmaceuticals has announced encouraging results showing its candidate could be a best-in-class treatment for relapsed and refractory chronic myeloid leukaemia (CML).   The Phase I trial of TERN-701 showed a 64% major molecular response (MMR) achievement rate across all efficacy evaluable patients, also proving its safe and… Read More

#Cancer Research #News

CAR-T for large B-cell lymphoma
#Advanced Therapies #Bristol Myers Squibb #FDA #Haematology #Lymphoma #Oncology

FDA approves first CAR-T therapy for marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of… Read More

#News #Regulatory

Osteosarcoma
#Oncology #Osteosarcoma #Paediatrics

Looking back to see forward: The future of osteosarcoma treatment

An overview of osteosarcoma epidemiology and treatment landscape to guide the future of therapeutic intervention. Osteosarcoma is a rare, aggressive form of bone cancer primarily affecting children and young adults. It is well recognised there continues to exist a critical unmet need in paediatric oncology due to outdated treatments with… Read More

#Exclusive Content

Red blood cells
#ASH 2025 #Blood can #JAK inhibitor #Myelofibrosis (MF) #Oncology

ASH 2025: Combined focus on myelofibrosis

More than a decade after first JAK approval, pharma looks to combination therapies to treat myelofibrosis. Pharma and biotech companies are looking to combination therapies for a new wave of treatments for the rare bone cancer myelofibrosis, building on the experience gathered over more than a decade with JAK inhibitors,… Read More

#Exclusive Content

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

#Financing #Oncology #One-carbon Therapeutics #Solid tumours

One-carbon closes oversubscribed private placement financing

One-carbon Therapeutics has closed an oversubscribed 153 million SEK ($16.2 million) private placement financing round supported by current and new investors and private Swedish family offices.  The company says it will use the net proceeds from the private placement to strengthen its financial position and expand its ongoing Phase I/II… Read More

#Business & Investment #News

Biliary tract
#Biliary tract cancer #Chemotherapy #Oncology #Pusan National University #Yonsei University

Study finds new treatment option for biliary tract cancer

Researchers have found that that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer (BTC) patients.  A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards… Read More

#Cancer Research #News

Prostate cancer cells
#Gilead Sciences #Mergers and acquisitions #Oncology #Sprint Bioscience

Gilead buys Sprint Bioscience’s TREX1 cancer programme

Gilead Sciences has acquired the TREX1 cancer programme from Sprint Bioscience for an upfront payment of $14 million plus milestone payments up to $400 million.  The objective of the TREX1 programme, which is in the preclinical phase, is to develop drugs that inhibit the TREX1 protein in order to enhance… Read More

#Business & Investment #News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Oncology #Osteosarcoma #UK government

DDW Highlights: 25 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More

#Podcasts

Water molecules
#Cancer research #Computational chemistry #Oncology #The Institute of Cancer Research

Study reveals how water influences cancer drug potency

Researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding.  The study focused on B-cell lymphoma 6 (BCL6), a protein implicated in several cancers. Using advanced computational techniques, the team showed how subtle changes in drug molecules can disrupt or… Read More

#Cancer Research #Editor's Choice #News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Nuclear medicine #Oncology #Osteosarcoma #UK government

This week in Drug Discovery (17 – 21 November) 

News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW.  This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer.  The top stories:    Medication detrimental to gut microbiome,… Read More

#News

#Domain Therapeutics #GPCRs #New appointment #Oncology

New Domain chief medical officer to advance GPCR pipeline

Domain Therapeutics has announced the appointment of Dr Jean-Marie Cuillerot as Chief Medical Officer (CMO).  Dr Cuillerot brings pharmaceutical and biotech experience, with a track record in leading successful clinical development programmes and regulatory strategy.   Earlier in his career, Dr Cuillerot served as the medical lead at Bristol-Myers Squibb… Read More

#Business & Investment #News